Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Five years after cancer treatment, many survivors still suffer symptoms

When people finish treatment for cancer, they want to bounce back to their former vital selves as quickly as possible. But a new Northwestern Medicine study -- one of the largest survivor studies ever conducted - shows many survivors still suffer moderate to severe problems with pain, fatigue, sleep, memory and concentration three to five years after treatment has ended.

4 Jun 2011

SBRT is effective for patients with low-to-intermediate-risk prostate cancer: Researchers

In a multicenter clinical trial, UT Southwestern Medical Center researchers have found that higher doses of stereotactic radiation therapy requiring fewer treatments are safe and effective for patients with low-to-intermediate-risk prostate cancer.

4 Jun 2011

Delayed treatment could prove effective in certain medical conditions

In today's fast-paced world, waiting — whether it's at the doctor's office, in line at the grocery store or for an Internet connection — is rarely considered a good thing.

3 Jun 2011

ZYTIGA clinical study data on prostate cancer to be presented at ASCO 2011

Data related to ZYTIGA (abiraterone acetate) will be presented at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

3 Jun 2011

APC8015F investigational vaccine improves survival of prostate cancer patients

Metastatic prostate cancer patients who received an investigational vaccine made from their own frozen immune cells lived 10 months longer than those not treated with it, according to data being presented by researchers from the Kimmel Cancer Center at Jefferson at the 2011 American Society of Clinical Oncology annual meeting in Chicago on Saturday, June 4.

3 Jun 2011

Itraconazol may keep prostate cancer from worsening and delay need for chemotherapy in men

The oral antifungal drug itraconazole, most commonly used to treat nail fungus, may keep prostate cancer from worsening and delay the need for chemotherapy in men with advanced disease.

3 Jun 2011

Stereotactic body radiation therapy effective for patients with low-risk prostate cancer

3 Jun 2011

PCF funds 14 new Creativity Awards for advanced prostate cancer research

The Prostate Cancer Foundation today announced that it has funded 14 new Creativity Awards for advanced prostate cancer research. These two-year awards are designed to support innovative research ideas that have the potential to achieve breakthroughs for improved prostate cancer diagnosis and treatment.

2 Jun 2011

IMRT cuts GI side effects from prostate cancer in half vs. 3D-CRT

Intensity modulated radiation therapy, a newer, more precise form of radiation therapy, causes fewer gastrointestinal side effects when combined with hormone therapy than using three-dimensional radiation therapy, according to a study published in the June issue of the International Journal of Radiation Oncology·Biology·Physics, the official scientific journal of the American Society for Radiation Oncology (ASTRO).

1 Jun 2011

Scientists find no link between XMRV retrovirus and human disease

Delineation of the origin of the retrovirus known as XMRV from the genomes of laboratory mice indicates that the virus is unlikely to be responsible for either prostate cancer or chronic fatigue syndrome in humans, as has been widely published.

1 Jun 2011

Chronic fatigue syndrome and mouse virus – no association

An earlier study published in 2009 had claimed that a mouse virus was the cause of chronic fatigue syndrome. New evidence suggests that this assumption is wrong. According to latest evidence the earlier study findings were likely based on contaminated lab samples, US researchers said Tuesday.

1 Jun 2011

Exposure to pesticides near any workplace increases risk of Parkinson's disease

In April 2009, researchers at UCLA announced they had discovered a link between Parkinson's disease and two chemicals commonly sprayed on crops to fight pests.

27 May 2011

Research sheds light on how painkillers could prevent or slow down cancer growth

CANCER RESEARCH UK scientists have shed light on how a common class of painkillers - which includes ibuprofen - may interact with a key protein that fuels the growth of many different types of cancer, according to a study published in the journal Chemical Communications today.

27 May 2011

Abiraterone acetate effective for men with advanced prostate cancer

A drug recently approved by the Food & Drug Administration for the treatment of prostate cancer is proving to give some patients the gift of time. A new study shows abiraterone acetate extends the lives of men with the most advanced form of the disease by about four months.

27 May 2011

Turkey tail mushrooms effective in prostate cancer: study

Preliminary studies have shown that mushrooms used in Asia for medicinal purposes vanquished prostate tumor successfully in mice.

26 May 2011

NWBT accelerates addition of clinical sites for new enrollment into ongoing GBM brain cancer trial

Northwest Biotherapeutics today announced that it has accelerated the addition of clinical trial sites, exceeding its projections for the doubling of such sites across the U.S. this calendar quarter, for enrollment of new patients into the Company's ongoing 240-patient randomized, double blind, placebo controlled clinical trial of DCVax immune therapy for Glioblastoma multiforme, the most lethal form of brain cancer.

26 May 2011

NEJM publishes ZYTIGA plus prednisone Phase 3 trial data in metastatic castration-resistant prostate cancer

A study titled "Abiraterone and Increased Survival in Metastatic Prostate Cancer," published in the May 26 issue of NEJM, found that patients with metastatic castration-resistant prostate cancer who have received prior chemotherapy containing docetaxel showed a significant improvement in overall survival when treated with ZYTIGA plus prednisone compared to patients treated with prednisone plus placebo.

26 May 2011

New findings from STELARA psoriasis clinical trial to be presented at 22nd World Congress of Dermatology

New findings to be presented from pooled analyses of the STELARA psoriasis clinical development program showed that the safety profile of STELARA and rates of adverse events remained consistent and stable over time in adults with moderate to severe plaque psoriasis receiving up to four years of treatment.

25 May 2011

Brisk walking may delay or even prevent progression of prostate cancer in men

Men with prostate cancer can improve their outcomes if they walk briskly for at least three hours a week following their diagnosis, according to a recent study in Cancer Research, a journal of the American Association for Cancer Research.

25 May 2011

Some African descent men may have higher genetic risk of developing prostate cancer

Some men of African descent may have a higher genetic risk of developing prostate cancer, according to research conducted at the Keck School of Medicine of the University of Southern California.

24 May 2011